Similar to vertical sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB) is also a bariatric procedure that not only aids in weight loss but also relieves NAFLD symptoms by altering ghrelin and LEAP-2 concentrations in relation to pro-fibrotic factors. This evidence concerns the gene LEAP2 and metabolic dysfunction-associated steatotic liver disease.